CAPR News and Press, Capricor Therapeutics Inc. From 03/28/22

A phase 2 trial of Capricor Therapeutics' (NASDAQ:CAPR) COVID-19 treatment CAP-1002 met its primary objective of safety. Although the study was not powered to determine efficacy, overall mortality was 20%. There were six deaths in the placebo group and five in the CAP-1002 group. Patients enr...

-Primary Objective of Study Met: CAP-1002 was Safe and Well Tolerated- SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics, announced to...

-One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients- -Data Sets Stage for Pivotal Phase 3 HOPE-3 Clinical Trial- SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- Ca...

Capricor Therapeutics, Inc. (CAPR) Q4 2021 Earnings Conference Call March 10, 2022 4:30 PM ET Company Participants AJ Bergmann - Chief Financial Officer Linda Marban - Chief Executive Officer Conference Call Participants Emanuela Branchetti - H.C. Wainwright Presentation Operator 00:05 Good d...

Capricor Therapeutics press release (NASDAQ:CAPR): Q4 GAAP EPS of -$0.26. Company’s cash and cash equivalents totaled approximately $34.9 million as of December 31, 2021, compared to approximately $32.7 million on December 31, 2020.  Shares +10% AH. For further details see: ...

CAP-1002 Cell Therapy Programs -Pivotal Phase 3, HOPE-3 Trial Initiation Underway- -Entered Exclusive Partnership with Nippon Shinyaku for Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in United States- -Capricor to Receive Up...

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial resul...

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today the expansion of...

Gainers: BioCardia (NASDAQ:BCDA) +30%. Aptorum Group (NASDAQ:APM) +22%. Bon Natural Life (NASDAQ:BON) +17%. Lightning eMotors (NYSE:ZEV) +15%. Modine Manufacturing (NYSE:MOD) +14%. Battalion Oil (NYSE:BATL) +13%. DXC Technology (NYSE:DXC) +12%. Redwire (NYSE:RDW) +11%. T-Mobile US (NASDAQ:TMU...

Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US PR Newswire KYOTO, Japan , Jan. 25, 2022 /PRNewswire/ -- *NS Pharma Note: CA...